Dossier assessment
Toripalimab (oesophageal carcinoma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Toripalimab (oesophageal carcinoma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Toripalimab (oesophageal carcinoma) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Toripalimab (oesophageal carcinoma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
- Patients with tumour cell PD-L1 expression ≥ 1% or a combined positive score ≥ 10; first-line treatment: added benefit not proven
- Patients with no tumour cell PD-L1 expression ≥ 1% and no combined positive score ≥ 10; first-line treatment: added benefit not proven
Project details
- Project no.
- A26-05
- Commission
- Commission awarded on 14.01.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-05
Connected Projects
-
Dossier assessment
Toripalimab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed